7T MRI for Light Therapy in Patients With Mild Cognitive Impairment and Mild AD

NACompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

February 28, 2023

Primary Completion Date

May 30, 2025

Study Completion Date

May 30, 2025

Conditions
Mild Cognitive ImpairmentAlzheimer's Disease
Interventions
DEVICE

Lighting Intervention Therapy

The LIT will provide high circadian stimulation during the day produced by light sources that provide moderate light levels of spectra that are tuned to the sensitivity of the circadian system. The TLI intervention will remain in place and will be delivered to participants for 10 weeks each in a counterbalanced manner. Combining spectrum and light level, LIT will allow the research team to: (a) use a light source that will stimulate the circadian system, and (b) provide the participants with options as to how the light treatment will be delivered. The research team will deliver at least 300-400 lux at the eye of the bluish-white light during the day (CS of 0.4 or greater) and about 50 lux at the eye during the evening hours (CS of less than 0.1) and when the control lighting intervention is used.

DEVICE

Sham LIT

A placebo comparison lighting intervention will be used. The comparison lighting intervention will remain in place and will be delivered to participants for 10 weeks.

Trial Locations (1)

10029

Icahn School of Medicine at Mount Sinai, New York

All Listed Sponsors
collaborator

National Institute on Aging (NIA)

NIH

lead

Icahn School of Medicine at Mount Sinai

OTHER